CureVac NV (XTER:5CV)
€ 2.966 0.222 (8.09%) Market Cap: 682.36 Mil Enterprise Value: 167.57 Mil PE Ratio: 5.46 PB Ratio: 0.85 GF Score: 56/100

CureVac NV Preliminary Phase 1 Data from Joint COVID-19 and Flu mRNA Vaccine Development Programs Transcript

Jan 06, 2023 / 02:00PM GMT
Release Date Price: €7.38 (+21.99%)
Operator

Greetings. Welcome to CureVac's Preliminary Phase I Data from Joint COVID-19 and Flu mRNA Vaccine Development Program. This time all participant are in listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions). Please note this conference is being recorded. At this time, I'll now turn the conference over to Sarah Fakih, Vice President, Corporate Communications and Investor Relations. Ms. Fakih, you may now begin.

Sarah Fakih
CureVac N.V. - VP Corporate Communications & IR

Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih, and I'm the Vice President of Corporate Communications and Investor Relations at CureVac. Please let me introduce today's speakers. On the call with me from CureVac are Franz-Werner-Haas, our Chief Executive Officer; and Ulrike Gnad-Vogt, our Interim Chief Development Officer.

Please note that this call is being webcast live and will be archived on the Events & Presentations section under Investor Relations on our website.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot